THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN

Autor:	Minggao Shi, Karen Brown, Dolly A. Parasrampuria, Prachi Wickremasingha, Victor Dishy, Jarema Kochan
Jazyk:	angličtina
Předmět:	chemistry.chemical_compound medicine.drug_mechanism_of_action chemistry Edoxaban business.industry Clinical investigation Factor Xa Inhibitor medicine Pharmacology Cardiology and Cardiovascular Medicine business Prothrombin complex concentrate medicine.drug
Zdroj:	Journal of the American College of Cardiology. (12):A2095
ISSN:	0735-1097
DOI:	10.1016/S0735-1097(14)62098-2
Popis:	Edoxaban (Edox) is a novel oral, once-daily, direct factor Xa inhibitor currently under clinical investigation. To date, there is no established paradigm to reverse Edox activity in cases of clinically relevant bleeding. We evaluated the use of 3-factor prothrombin complex concentrate (PCC; Bebulin
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab11087397a050c5221089d4c26800a8 Zobrazit plný text záznamu